News

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...
A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...
Patent Extension Regulatory Review Period: Beyfortus An unpublished Notice by the Food and Drug Administration on 06/16/2025 Document Details. Public Inspection Content - Document Details. Filed at 06 ...
Another RSV antibody called Beyfortus, made by Sanofi and AstraZeneca, was approved in 2023. But there were supply shortages during last year’s RSV season.
The U.S. Food and Drug Administration (FDA) has approved a monoclonal antibody called Enflonsia, the drugmaker Merck announced June 9.. Given as a single 105-milligram injection, Enflonsia is designed ...
Enter a search term or FR citation e.g. 88 FR 382 30 FR 7878 2024-13208 USDA 09/05/24 RULE 0503-AA39 SORN Choosing an item from full text search results will bring you to those results. Pressing enter ...
Both Beyfortus and Enflonsia have strong efficacy and safety profiles. Beyfortus and Enflonsia are expected to completely replace the use of Sobi’s Synagis (palivizumab), an older mAb which requires ...
Once commercially launched, Merck’s Enflonsia will face stiff competition from AstraZeneca AZN/Sanofi’s SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023.